Monte Rosa Therapeutics Inc
GLUE4.809USD
+0.019+0.40%
交易中 （美东）报价延迟15分钟
295.80M总市值
48.07市盈率 TTM
关于 Monte Rosa Therapeutics Inc 公司
Monte Rosa Therapeutics, Inc. 是一家临床阶段的生物技术公司。该公司致力于为患有肿瘤和自身免疫等领域严重疾病的患者开发一系列新型分子胶降解剂 (MGD)。MGD 是小分子药物，利用人体天然的蛋白质破坏机制选择性地降解治疗相关蛋白质。该公司开发了一种降解平台，称为定量和工程化消除新底物 (QuEEN)，以实现以目标为中心的 MGD 发现和开发方法以及 MGD 产品候选物的合理设计。其产品候选物 MRT-2359 是一种口服生物可利用的 MGD，靶向翻译终止因子蛋白 GSPT1。MRT-2359 正在进行临床开发，可能用于 MYC 驱动的肿瘤，包括转移性非小细胞肺癌、小细胞肺癌和神经内分泌肿瘤。其其他产品候选物包括 MRT-6160 和 MRT-8102。
公司简介
公司代码GLUE
公司名称Monte Rosa Therapeutics Inc
上市日期Jun 24, 2021
CEODr. Markus Warmuth, M.D.
员工数量134
证券类型Ordinary Share
年结日Jun 24
公司地址321 Harrison Avenue
城市BOSTON
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编02118
电话16179492643
网址https://www.monterosatx.com/
公司代码GLUE
上市日期Jun 24, 2021
CEODr. Markus Warmuth, M.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Sharon Townson, Ph.D.
Dr. Sharon Townson, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
36.00K
--
Ms. Jennifer Champoux
Ms. Jennifer Champoux
Chief Operating Officer
Chief Operating Officer
30.00K
--
Dr. Filip Janku, M.D., Ph.D.
Dr. Filip Janku, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
9.19K
-74.47%
Dr. Philip Nickson, J.D., Ph.D.
Dr. Philip Nickson, J.D., Ph.D.
Chief Business and Legal Officer
Chief Business and Legal Officer
--
-100.00%
Dr. Kimberly L. Blackwell, M.D.
Dr. Kimberly L. Blackwell, M.D.
Independent Director
Independent Director
--
--
Dr. Markus Warmuth, M.D.
Dr. Markus Warmuth, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Anthony M. Manning, Ph.D.
Dr. Anthony M. Manning, Ph.D.
Independent Director
Independent Director
--
--
Ms. Christine Siu
Ms. Christine Siu
Independent Director
Independent Director
--
--
Dr. Chandra P. Leo, M.D.
Dr. Chandra P. Leo, M.D.
Independent Director
Independent Director
--
--
Dr. Andrew N. (Drew) Schiff, M.D.
Dr. Andrew N. (Drew) Schiff, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Sharon Townson, Ph.D.
Dr. Sharon Townson, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
36.00K
--
Ms. Jennifer Champoux
Ms. Jennifer Champoux
Chief Operating Officer
Chief Operating Officer
30.00K
--
Dr. Filip Janku, M.D., Ph.D.
Dr. Filip Janku, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
9.19K
-74.47%
Dr. Philip Nickson, J.D., Ph.D.
Dr. Philip Nickson, J.D., Ph.D.
Chief Business and Legal Officer
Chief Business and Legal Officer
--
-100.00%
Dr. Kimberly L. Blackwell, M.D.
Dr. Kimberly L. Blackwell, M.D.
Independent Director
Independent Director
--
--
Dr. Markus Warmuth, M.D.
Dr. Markus Warmuth, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 7月28日 周一
更新时间: 7月28日 周一
持股股东
股东类型
持股股东
持股股东
占比
New Enterprise Associates (NEA)
12.51%
T. Rowe Price Associates, Inc.
10.66%
BVF Partners L.P.
9.20%
Versant Ventures
9.19%
Baker Bros. Advisors LP
7.99%
Other
50.45%
持股股东
持股股东
占比
New Enterprise Associates (NEA)
12.51%
T. Rowe Price Associates, Inc.
10.66%
BVF Partners L.P.
9.20%
Versant Ventures
9.19%
Baker Bros. Advisors LP
7.99%
Other
50.45%
股东类型
持股股东
占比
Investment Advisor
32.75%
Hedge Fund
25.10%
Venture Capital
24.08%
Investment Advisor/Hedge Fund
17.31%
Research Firm
1.15%
Individual Investor
0.85%
Sovereign Wealth Fund
0.72%
Pension Fund
0.11%
Bank and Trust
0.10%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
229
62.87M
102.21%
-2.01M
2025Q1
235
60.82M
98.88%
-7.09M
2024Q4
220
61.73M
100.63%
-766.83K
2024Q3
200
57.64M
94.07%
-4.29M
2024Q2
191
55.42M
93.92%
+8.23M
2024Q1
185
49.41M
98.58%
+2.43M
2023Q4
187
49.83M
99.64%
+961.54K
2023Q3
187
51.89M
104.49%
+4.85M
2023Q2
202
40.69M
82.04%
-4.78M
2023Q1
192
47.34M
97.38%
+2.16M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
New Enterprise Associates (NEA)
7.69M
12.51%
--
--
Mar 31, 2025
T. Rowe Price Associates, Inc.
6.56M
10.66%
-475.63K
-6.76%
Mar 31, 2025
BVF Partners L.P.
5.66M
9.2%
+1.27M
+28.84%
Mar 31, 2025
Versant Ventures
5.65M
9.19%
--
--
Mar 31, 2025
Baker Bros. Advisors LP
4.92M
7.99%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
4.67M
7.6%
-874.34K
-15.76%
Mar 31, 2025
Avoro Capital Advisors LLC
4.65M
7.55%
+300.55K
+6.92%
Mar 31, 2025
Suvretta Capital Management, LLC
3.36M
5.46%
+1.80M
+114.86%
Apr 09, 2025
BlackRock Institutional Trust Company, N.A.
3.22M
5.24%
-73.74K
-2.24%
Mar 31, 2025
The Vanguard Group, Inc.
3.10M
5.04%
-56.32K
-1.78%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
0.83%
Royce Quant Small-Cap Quality Value ETF
0.19%
iShares Micro-Cap ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
Avantis US Small Cap Equity ETF
0.03%
iShares Biotechnology ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 ETF
0.01%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
占比0.83%
Royce Quant Small-Cap Quality Value ETF
占比0.19%
iShares Micro-Cap ETF
占比0.05%
ProShares Ultra Nasdaq Biotechnology
占比0.03%
Invesco Nasdaq Biotechnology ETF
占比0.03%
Avantis US Small Cap Equity ETF
占比0.03%
iShares Biotechnology ETF
占比0.02%
iShares Russell 2000 Value ETF
占比0.02%
ProShares UltraPro Russell2000
占比0.01%
iShares Russell 2000 ETF
占比0.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
